tetano
Editor, Senior Moderator
Cell Mol Immunol
. 2021 Sep 8.
doi: 10.1038/s41423-021-00752-2. Online ahead of print.
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du[SUP] 1 [/SUP], Yang Yang[SUP] 2 [/SUP], Xiujuan Zhang[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus-cell membrane fusion mediated by the S2 subunit, which allows virus entry into the host cell. Therefore, the SARS-CoV-2 S protein is a key therapeutic target, and prevention and treatment of coronavirus disease 2019 (COVID-19) have focused on the development of neutralizing monoclonal antibodies (nAbs) that target this protein. In this review, we summarize the nAbs targeting SARS-CoV-2 proteins that have been developed to date, with a focus on the N-terminal domain and RBD of the S protein. We also describe the roles that binding affinity, neutralizing activity, and protection provided by these nAbs play in the prevention and treatment of COVID-19 and discuss the potential to improve nAb efficiency against multiple SARS-CoV-2 variants. This review provides important information for the development of effective nAbs with broad-spectrum activity against current and future SARS-CoV-2 strains.
Keywords: COVID-19; Monoclonal antibodies; Neutralization; SARS-CoV-2; Spike protein.
. 2021 Sep 8.
doi: 10.1038/s41423-021-00752-2. Online ahead of print.
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du[SUP] 1 [/SUP], Yang Yang[SUP] 2 [/SUP], Xiujuan Zhang[SUP] 3 [/SUP]
Affiliations
- PMID: 34497376
- DOI: 10.1038/s41423-021-00752-2
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus-cell membrane fusion mediated by the S2 subunit, which allows virus entry into the host cell. Therefore, the SARS-CoV-2 S protein is a key therapeutic target, and prevention and treatment of coronavirus disease 2019 (COVID-19) have focused on the development of neutralizing monoclonal antibodies (nAbs) that target this protein. In this review, we summarize the nAbs targeting SARS-CoV-2 proteins that have been developed to date, with a focus on the N-terminal domain and RBD of the S protein. We also describe the roles that binding affinity, neutralizing activity, and protection provided by these nAbs play in the prevention and treatment of COVID-19 and discuss the potential to improve nAb efficiency against multiple SARS-CoV-2 variants. This review provides important information for the development of effective nAbs with broad-spectrum activity against current and future SARS-CoV-2 strains.
Keywords: COVID-19; Monoclonal antibodies; Neutralization; SARS-CoV-2; Spike protein.